EGFR and non-small cell lung carcinoma: Despite these limitations, to the best of our knowledge, this is the first Pakistani study to analyse OS associated with TKI therapy, offering valuable national evidence on survival factors in EGFR-positive NSCLC patients treated with TKIs as first-line therapy.